news
FDA reviews Nanoscope's one-time gene therapy for severe vision loss
Nanoscope Therapeutics' MOGENRY (sonpiretigene isteparvovec), an optogenetic gene therapy, is now under FDA review. It's a single-dose intravitreal injection for retinitis pigmentosa patients with severe vision loss, aiming to restore sight and improve quality of life.
Nanoscope Therapeutics' MOGENRY (sonpiretigene isteparvovec), an optogenetic gene therapy, is now under FDA review. It's a single-dose intravitreal injection for retinitis pigmentosa patients with severe vision loss, aiming to restore sight and improve quality of life.
The architecture take
The FDA looking at Nanoscope's gene therapy for vision loss isn't just about eyes; it's a huge nervous system play. This therapy tries to make retinal cells light-sensitive again, essentially re-wiring how the brain processes visual input. Losing your sight messes with your whole sensory baseline, often tanking mental health and disrupting circadian rhythms because light signals are off. If this works, it changes more than just seeing; it re-calibrates a person's entire internal state and capacity for regulation. I saw a friend struggle with RP, and the ripple effects were profound. This isn't a cure for all blindness, but it’s a big step toward addressing the profound nervous system impact of sensory loss. Keep an eye on how these gene therapies address wider quality-of-life biomarkers, not just visual acuity.